Scientists at Sanford Burnham Prebys Medical Discovery Institute, University of California San Diego School of Medicine and Hopp Children’s Cancer Center Heidelberg (KiTZ) have demonstrated that personalised drug screens can be used to identify new therapeutic candidates for medulloblastoma, the most common malignant brain cancer in children.
The approach measures the effectiveness of therapeutics using tumour cells obtained from a biopsy and can be performed in a few days — making it one of the quickest sources of information used in clinical decision-making. Based on this proof-of-concept study, which was published in Cancer Research, a clinical trial using the approach is now planned.
“Our findings show that personalised drug screens can help us move away from a one-size-fits-all approach to treating medulloblastoma patients,” says Robert Wechsler-Reya, Ph.D., the corresponding author of the study, professor and director of the Tumor Initiation and Maintenance Program at Sanford Burnham Prebys, and program director of the Joseph Clayes III Research Center for Neuro-Oncology and Genomics at the Rady Children’s Institute for Genomic Medicine.
“We have shown that we can identify therapies that cannot be predicted using other methods and that the results can be used in clinical decision-making to improve outcomes for patients. For children diagnosed with medulloblastoma and their parents, better treatments can’t arrive fast enough.”
Efforts to find personalised treatments for medulloblastoma, which comprises four distinct subgroups — WNT, Sonic hedgehog (SHH), Group 3 and Group 4 — have not been successful to date. Most patients still receive the same treatments — brain surgery to remove the tumour followed by radiation and chemotherapy — in spite of the different molecular characteristics of the tumours. As a result, one-third of children succumb to cancer; and the children who do survive often have severe, lifelong side effects from the treatment, including cognitive impairment and a greater likelihood of developing cancer again.
“Precision medicine has revolutionised the treatment of certain cancers. Now, we hope that personalized drug screens will expand these benefits to children with brain cancer,” says John Crawford, M.D., a co-author of the study and director of the Neuro-Oncology Program at Rady Children’s Hospital-San Diego.
“Personalised drug screens allow us to tailor therapy to each patient’s tumour, potentially saving the lives of more children and protecting others from the devastating long-term side effects of receiving chemotherapy and radiation at such a young age.”
Expanding the “medicine cabinet”
In the study, the scientists initially screened medulloblastoma tumours from patient-derived xenografts (PDX), models created by transplanting a patient’s brain tumour into mice, against a drug library containing nearly 5,000 compounds. The screen identified several drugs that halted the growth of cells from Group 3 medulloblastoma, the deadliest form of the disease; and one of these drugs, actinomycin D, extended the survival of mice harbouring the corresponding PDX model.
“We are very excited that this screen revealed a drug that may be effective against Group 3 medulloblastoma, which is the most aggressive subtype,” says Jessica Rusert, Ph.D., lead author of the study and postdoctoral researcher in the Wechsler-Reya lab. “Actinomycin D has been used since the 1950s to treat other pediatric cancers, which means we have extensive information about its safety in children, and thus it could be moved relatively quickly into human testing.”
Actinomycin D also appeared to work better than some of the standard-of-care chemotherapies, offering a glimmer of hope that it might be able to replace the harsh treatment regimen that leaves some children with serious long-term side effects.
A leap from lab to clinic
To confirm that this approach could be used in the real world, the scientists completed a “test run” using a brain tumour removed from an 8-year-old boy newly diagnosed with metastatic medulloblastoma.
A personalised drug screen identified several drugs that may work for his tumour type, and the results were reviewed by a molecular tumour board — a panel of physicians and scientists who work together to discuss treatment options.
Although per protocol, the child continued with standard-of-care treatment, the results showed that a personalized treatment plan could have been created in time to guide care decisions. (ANI)
